LAUREN TILLMAN: Open Payments
NPI 1629576368 · NEWBURGH, IN. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$2,172 in 110 payments from 17 companies in 2025. Trend: 2023 $1,789 · 2024 $1,440 · 2025 $2,172
Food & beverage: $2,172
| Company | Payments | Amount |
|---|---|---|
| ABBVIE INC. | 29 | $509 |
| Janssen Biotech, Inc. | 14 | $326 |
| Salix Pharmaceuticals, a division of Bausch Health US, LLC | 14 | $257 |
| Gilead Sciences, Inc. | 8 | $159 |
| NeurAxis, Inc. | 1 | $144 |
| Takeda Pharmaceuticals U.S.A., Inc. | 6 | $116 |
| Lilly USA, LLC | 6 | $113 |
| Madrigal Pharmaceuticals | 4 | $94 |
| Regeneron Healthcare Solutions, Inc. | 4 | $91 |
| Ardelyx, Inc. | 5 | $83 |
Products named: TREMFYA, XIFAXAN, RINVOQ, CREON, DUPIXENT, OMVOH, LINZESS, REZDIFFRA.
Industry payments across IN — which companies pay providers there.
